Overview

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

Status:
Completed
Trial end date:
2016-03-15
Target enrollment:
Participant gender:
Summary
This study is an opportunity for Boehringer Ingelheim to collaborate with Humana to conduct comparative safety and effectiveness studies of dabigatran and warfarin using real world data from Humana's health plan operations.
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Dabigatran
Warfarin